Pre-Market Review: VIVUS Inc., Sanofi, DENTSPLY Intl. Inc., and Acura Pharmaceuticals Inc. Editor Note: For more information about this release, please scroll to bottom. PR Newswire LONDON, October 16, 2013 LONDON, October 16, 2013 /PRNewswire/ -- The U.S. equity markets edged lower on Tuesday, October 15, 2013, with the S&P 500, the Dow Jones Industrial Average, and the NASDAQ Composite falling by 0.71%, 0.87%, and 0.56%, respectively. Shares in the healthcare sector finished on a lower note as the broader market posted losses. The major movers in the sector included Vivus Inc. (NASDAQ: VVUS) Sanofi (NYSE: SNY), DENTSPLY International Inc. (NASDAQ: XRAY), and Acura Pharmaceuticals Inc. (NASDAQ: ACUR). AAAResearchReports.com initiated preliminary technical research on VVUS, SNY, XRAY, and ACUR. These free reports are accessible by signing today at: http://www.aaaresearchreports.com/register/ Vivus Inc.'s stock plummeted on Tuesday, tracking losses in the broader market. The company's shares closed the day at$10.06, down 4.19%, after oscillating between$9.99 and $10.50. A total of 2.97 million shares were traded, which is above the daily average volume of 2.63 million. The company's shares have lost 0.59% in the previous one month, compared to a gain of 0.60% in the S&P 500 during the same period. Furthermore, Vivus Inc.'s stock is trading below its 50-day and 200-day moving averages of $11.42 and $12.51, respectively. The free technical analysis on VVUS is available by signing up at: http://www.AAAResearchReports.com/VVUS101613.pdf On Tuesday, Sanofi's stock ended the session 1.62% lower than the previous day's price of $50.10. The company's shares oscillated between $49.29 and $49.68 before closing the day at $49.29. A total of 0.58 million shares were traded, which is significantly below the daily average volume of 2.05 million. The company's shares have gained 2.77% in the previous one month, outperforming the S&P 500 which has gained 0.60% during the same period. Further, Sanofi's stock is also trading below its 50-day and 200-day moving averages of $50.17 and $50.86, respectively. Register now to download free research on SNY at: http://www.AAAResearchReports.com/SNY101613.pdf DENTSPLY International Inc.'s stock declined 0.98% on Tuesday, reversing all the gains from the previous trading session. The company's shares vacillated between $44.15 and $44.63 before closing the day at $44.29. A total of 0.72 million shares were traded, which is marginally below the daily average volume of 0.75 million. Despite Tuesday's pullback, the company's shares have advanced 5.45% in the previous three months and 0.45% in the last three trading sessions, compared to a gain of 0.92% and 0.32% in the S&P 500 during the respective periods. Moreover, DENTSPLY International Inc.'s stock is trading above its 50-day and 200-day moving averages of $43.19 and $42.11, respectively. A free report on XRAY can be accessed by registering at: http://www.AAAResearchReports.com/XRAY101613.pdf On Tuesday, Acura Pharmaceuticals Inc.'s stock plummeted 3.95%, as the U.S. equity market finished on a lower note. The company's shares ended the day at $1.70 after fluctuating between $1.70 and $1.77 during the trading session. A total of 0.49 million shares were traded, which is marginally above the daily average volume of 0.46 million. Despite yesterday's losses, the company's shares have surged 14.09% in the previous one month, outperforming the S&P 500 which has advanced 0.60% during the same period. Additionally, Acura Pharmaceuticals Inc.'s stock is still trading above its 50-day moving average of $1.68. Register with AAA Research Reports and download research on ACUR for free at: http://www.AAAResearchReports.com/ACUR101613.pdf ---- EDITOR NOTES: 1.This is not company news. We are an independent source and our views do not reflect the companies mentioned. 2.Information in this release is fact checked and produced on a best efforts basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below. 3.This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public. 4.If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com. 5.For any urgent concerns or inquiries, please contact us at compliance@EquityNewsNetwork.com. 6.Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration. COMPLIANCE PROCEDURE Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Ananya Ghosh, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be. NOT FINANCIAL ADVICE Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein. NO WARRANTY OR LIABILITY ASSUMED Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute. SOURCE AAA Research Reports Contact: Peter F. Jones; + 1 (646) 396-9126 (North America); firstname.lastname@example.org
Pre-Market Review: VIVUS Inc., Sanofi, DENTSPLY Intl. Inc., and Acura Pharmaceuticals Inc.